Independent register of U.S. FDA drug recalls · updated Oct 12, 2026
RxRecalls Get alerts

FDA Drug Recalls

14,806 recalls, newest first

Class II · Moderate risk

Mucinex Fast Max DM Max

Labeling: Label Mix-Up; Bottles of Mucinex Fast-Max liquid are correctly labeled on the front of the label, however the back of the bottle where the Drug Facts labeling is, is missing certain Active Ingredients such as acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, and/or guaifenesin. As a result certain safety warnings associated with those ingredients may also be missing.

Terminated Labeling / mix-up Reckitt Benckiser LLC NDC 63824-019-66 D-1369-2015
Class I · High risk

Mucinex Fast Max Day Time Severe Congestion & Cough Night Time Cold & Flu

Labeling: Label Mix-Up; Bottles of Mucinex Fast-Max liquid are correctly labeled on the front of the label, however the back of the bottle where the Drug Facts labeling is, is missing certain Active Ingredients such as acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, and/or guaifenesin. As a result certain safety warnings associated with those ingredients may also be missing.

Terminated Labeling / mix-up Reckitt Benckiser LLC NDC 63824-528-22 D-1368-2015
Class I · High risk

Mucinex Fast Max Severe Congestion & Cough

Labeling: Label Mix-Up; Bottles of Mucinex Fast-Max liquid are correctly labeled on the front of the label, however the back of the bottle where the Drug Facts labeling is, is missing certain Active Ingredients such as acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, and/or guaifenesin. As a result certain safety warnings associated with those ingredients may also be missing.

Terminated Labeling / mix-up Reckitt Benckiser LLC NDC 63824-014-66 D-1367-2015
Class I · High risk

Mucinex Fast Max Day Time Severe Cold and Fast-Max Night Time Cold & Flu Two - 6 fl oz

Labeling: Label Mix-Up; Bottles of Mucinex Fast-Max liquid are correctly labeled on the front of the label, however the back of the bottle where the Drug Facts labeling is, is missing certain Active Ingredients such as acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, and/or guaifenesin. As a result certain safety warnings associated with those ingredients may also be missing.

Terminated Labeling / mix-up Reckitt Benckiser LLC NDC 63824-526-22 D-1366-2015
Class I · High risk

Mucinex Fast-Max Cold & Sinus

Labeling: Label Mix-Up; Bottles of Mucinex Fast-Max liquid are correctly labeled on the front of the label, however the back of the bottle where the Drug Facts labeling is, is missing certain Active Ingredients such as acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, and/or guaifenesin. As a result certain safety warnings associated with those ingredients may also be missing.

Terminated Labeling / mix-up Reckitt Benckiser LLC NDC 63824-016-66 D-1365-2015
Class I · High risk

Mucinex Fast Max Night Time Cold & Flu

Labeling: Label Mix-Up; Bottles of Mucinex Fast-Max liquid are correctly labeled on the front of the label, however the back of the bottle where the Drug Facts labeling is, is missing certain Active Ingredients such as acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, and/or guaifenesin. As a result certain safety warnings associated with those ingredients may also be missing.

Terminated Labeling / mix-up Reckitt Benckiser LLC NDC 63824-500-66 D-1364-2015
Class I · High risk

Mucinex Fast Max Cold

Labeling: Label Mix-Up; Bottles of Mucinex Fast-Max liquid are correctly labeled on the front of the label, however the back of the bottle where the Drug Facts labeling is, is missing certain Active Ingredients such as acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, and/or guaifenesin. As a result certain safety warnings associated with those ingredients may also be missing.

Terminated Labeling / mix-up Reckitt Benckiser LLC NDC 63824-015-66 D-1363-2015
Class III · Low risk

Cetirizine HCl Chewable Tablet

Failed Impurities/Degradation Specifications: An out of specification (OOS) result was reported for impurity at the 21 month stability time point.

Terminated Impurity / degradation Sandoz, Inc NDC 66394-041-06 D-1115-2015
Class I · High risk

HEPARIN Sodium Injection USP 25

Presence of Particulate Matter: The firm produced products using 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP which were subsequently recalled by the manufacturer due to the presence of particulate matter.

Terminated Particulate / foreign matter Pharmedium Services, LLC NDC 61553-419-02 D-1357-2015
Class I · High risk

HEPARIN Sodium Injection USP

Presence of Particulate Matter: The firm produced products using 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP which were subsequently recalled by the manufacturer due to the presence of particulate matter.

Terminated Particulate / foreign matter Pharmedium Services, LLC NDC 61553-418-02 D-1355-2015
Class II · Moderate risk

Fluoxetine Capsules USP

Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity in the API that exceeds the Threshold of Toxicological Concern (TTC) calculation for the impurity.

Terminated Chemical / undeclared Teva Pharmaceuticals USA NDC 50111-648-02 D-0971-2015
Class II · Moderate risk

Fluoxetine Capsules USP

Chemical Contamination: Product recalled due to an elevated level of a residual solvent impurity in the API that exceeds the Threshold of Toxicological Concern (TTC) calculation for the impurity.

Terminated Chemical / undeclared Teva Pharmaceuticals USA NDC 50111-647-01 D-0970-2015
Class I · High risk

Testosterone Cypionate 200 mg/mL in Sesame oil

Incorrect Product Formulation: Vials labeled as Testosterone Cypionate 200 mg/mL in Sesame Oil are being recalled because they contains Estradiol Valerate 20 mg/mL.

Terminated cGMP deviation Stroheckers Inc Pharmacy D-1088-2015
Class III · Low risk

Monistat 1 Simple Cure

Marketed without an approved NDA/ANDA: The distributed units of Monistat 1 Simple Cure include only the 1200 mg vaginal suppository; the approved NDA requires both a 1200 mg vaginal suppository and the 2% topical cream.

Terminated Unapproved drug Medtech Products, Inc. NDC 63736-013-30 D-1077-2015

Recalls by year